先进的HER2阳性乳腺癌的第一线治疗方案的有效性和安全性:贝叶斯网络元分析
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Cancer innovation
|July 1, 2024
概括
皮罗丁尼布加上 trastuzumab 和 docetaxel 显示在晚期的 HER2 阳性乳腺癌中具有更高的疗效. 这种疗法可能是最佳的第一线治疗,可以改善无进展生存率和客观反应率.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
- 生物统计学 生物统计学
背景情况:
- 先进的HER2阳性乳腺癌治疗依赖于珀图祖马布,特拉斯图祖马布和多塞塔克塞尔.
- 新兴疗法需要对最佳的第一线治疗策略进行评估.
- 对先进的HER2阳性乳腺癌的新疗法进行比较的证据有限.
研究的目的:
- 进行一个网络元分析,比较先进的HER2阳性乳腺癌的第一线治疗方案.
- 评估各种治疗方案的疗效 (无进展生存率,客观反应率) 和安全性.
- 通过间接的治疗比较来确定最佳的第一线治疗.
主要方法:
- 系统审查和贝叶斯网络的元分析.
- 在PubMed,EMBASE和Cochrane图书馆的数据库中搜索到2023年12月.
- 分析了20项随机临床试验,涉及7094名患者和15种治疗方案.
主要成果:
- 与传统的trastuzumab和docetaxel相比,Pyrotinib加上trastuzumab和docetaxel显著改善了无进展生存 (PFS) (HR:0.41) 和客观响应率 (ORR).
- 珀图祖马布加上特鲁祖马布和多塞塔克塞尔也改善了PFS (HR:0.65) 和ORR.
- 基于pyrotinib的疗法在PFS和ORR方面排名最高;等级≥3不良事件的发生率相似.
结论:
- 皮罗丁尼布加上trastuzumab和dcetaxel可能是先进的HER2阳性乳腺癌的最佳一线治疗方法.
- 这种疗法在PFS和ORR方面提供了卓越的疗效.
- 这些发现为这群患者的临床决策提供了有价值的证据.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.6K
相关概念视频
Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Hazard Ratio
110
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
110
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
